Compare AU
Compare MQWS vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are MQWS and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
MQWS | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 61 |
Median incremental investment | $0 | $920.50 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,976.53 |
Average age group | N/A | 26 - 35 |
Key Summary
MQWS | DRUG | |
|---|---|---|
Strategy | MQWS.AX was created on 2023-11-22 by Macquarie. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to achieve a long-term total return (before fees and expenses) that exceeds the MSCI World ex Australia Index, in $A unhedged with net dividends reinvested. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Mq Walter Scott Glbl Eq Active ETF (Managed Fund) (100 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (75.92 %) Communication Services (33.53 %) Health Care (23.94 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 1.28 % | 0.57 % |
Key Summary
MQWS | DRUG | |
|---|---|---|
Issuer | Macquarie | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 1.28 % | 0.57 % |
Price | $10.43 | $8.27 |
Size | N/A | $195.730 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | 2.15 % | 1.89 % |
Market | ASX | ASX |
First listed date | 21/11/2023 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
MQWS | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 61 |
Median incremental investment | $0 | $920.50 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,976.53 |
Average age group | N/A | 26 - 35 |
Pros and Cons
MQWS | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
MQWS | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |